These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 19249390

  • 1. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
    Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M.
    Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
    [Abstract] [Full Text] [Related]

  • 2. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
    Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M.
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
    [Abstract] [Full Text] [Related]

  • 3. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
    Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, Hamilton G.
    Eur J Surg Oncol; 2009 Nov; 35(11):1164-8. PubMed ID: 19254831
    [Abstract] [Full Text] [Related]

  • 4. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
    Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M.
    Lung Cancer; 2007 Jun; 56(3):399-404. PubMed ID: 17316892
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
    Riedel F, Zaiss I, Herzog D, Götte K, Naim R, Hörmann K.
    Anticancer Res; 2005 Jun; 25(4):2761-5. PubMed ID: 16080523
    [Abstract] [Full Text] [Related]

  • 7. Serum nitric oxide levels in patients with head and neck squamous cell carcinoma.
    Kizilay A, Kalcioğlu MT, Ozuğurlu F, Ozyurt H, Aladağ I, Ozturan O, Akyol O.
    Kulak Burun Bogaz Ihtis Derg; 2007 Jun; 17(3):148-51. PubMed ID: 17873505
    [Abstract] [Full Text] [Related]

  • 8. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
    Linder S, Olofsson MH, Herrmann R, Ulukaya E.
    Expert Rev Mol Diagn; 2010 Apr; 10(3):353-9. PubMed ID: 20370591
    [Abstract] [Full Text] [Related]

  • 9. Clinical significance of serum M30 and M65 levels in melanoma.
    Tas F, Karabulut S, Serilmez M, Yildiz I, Sen F, Ciftci R, Duranyildiz D.
    Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T, Yanoma S, Nakamura Y, Shiono O, Kokatu T, Kubota A, Furukawa M, Tsukuda M.
    Am J Otolaryngol; 2005 Oct; 26(5):308-13. PubMed ID: 16137528
    [Abstract] [Full Text] [Related]

  • 12. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
    Bilici A, Ustaalioglu BB, Ercan S, Seker M, Yilmaz BE, Orcun A, Gumus M.
    Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
    Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B, Piiper A.
    J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.
    Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S.
    Cancer Biomark; 2009 Oct; 5(3):117-25. PubMed ID: 19407366
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
    Caballero M, Grau JJ, Blanch JL, Domingo-Domenech J, Auge JM, Jimenez W, Bernal-Sprekelsen M.
    Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inverse correlation between serum PGE2 and T classification in head and neck cancer.
    Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H, Knecht R.
    Head Neck; 2007 Mar; 29(3):244-8. PubMed ID: 17123309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.